Logo newsbot.ch


Pfizer AG applies to Swissmedic for authorisation of a second bivalent COVID-19 vaccine

2022-09-22 15:45:14
newsbot by content-proivder.ch GmbH
Quelle: Swiss Federal Council

Bern, 22.09.2022 - Pfizer AG has submitted an application to Swissmedic for authorisation of a further bivalent COVID-19 vaccine, writes the Swiss Federal Council.

The ready-to-use dispersion for injection contains both messenger RNA (mRNA) from the original Pfizer/BioNTech COVID-19 vaccine (Comirnaty®) and mRNA coding for the spike protein of Omicron variants BA.4 and BA.5. Swissmedic is examining the application for authorisation in a rolling submission procedure. Any change to a medicinal product can affect its safety, efficacy or quality.

Swissmedic is carefully examining the scientific data submitted. Specifically, the documentation must demonstrate that bivalent COVID-19 vaccines are just as effective against original virus strains as the previous vaccines and that safety has been established.

Furthermore, an additional benefit in respect of the new virus variants – in the case of SARS-CoV-2, Omicron BA.4 and BA.5 – must be demonstrated..

Suche nach Stichworten:

Pfizer applies Swissmedic authorisation second bivalent COVID-19 vaccine


Swiss Federal Council

Watching viruses fail

Swiss Federal Council

Die Lage auf dem Arbeitsmarkt im November 2022

Swiss Federal Council

21.9% rise in overnight stays in the Swiss hotel sector during the 2022 summer season

Swiss Federal Council

In 2020, unpaid work was worth CHF 434 billion

Swiss Federal Council

22% of intensive care hours for COVID-19 patients